These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36298791)

  • 1. Susceptibility to Resurgent COVID-19 Outbreaks Following Vaccine Rollouts: A Modeling Study.
    Neofotistos G; Angeli M; Mattheakis M; Kaxiras E
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    Fisman DN; Amoako A; Simmons A; Tuite AR
    PLoS One; 2024; 19(4):e0297093. PubMed ID: 38574059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S
    Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Singh BK; Walker J; Paul P; Reddy S; Gowler CD; Jernigan J; Slayton RB
    Vaccine; 2022 May; 40(23):3165-3173. PubMed ID: 35487811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States.
    Yang F; Tran TN; Howerton E; Boni MF; Servadio JL
    BMC Med; 2023 Aug; 21(1):321. PubMed ID: 37620926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the effect of the vaccination campaign on the COVID-19 pandemic.
    Angeli M; Neofotistos G; Mattheakis M; Kaxiras E
    Chaos Solitons Fractals; 2022 Jan; 154():111621. PubMed ID: 34815624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling waning and boosting of COVID-19 in Canada with vaccination.
    Childs L; Dick DW; Feng Z; Heffernan JM; Li J; Röst G
    Epidemics; 2022 Jun; 39():100583. PubMed ID: 35665614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of hybrid immunity on future COVID-19 epidemic waves.
    Le TP; Abell I; Conway E; Campbell PT; Hogan AB; Lydeamore MJ; McVernon J; Mueller I; Walker CR; Baker CM
    BMC Infect Dis; 2024 Apr; 24(1):407. PubMed ID: 38627637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical modelling of vaccination rollout and NPIs lifting on COVID-19 transmission with VOC: a case study in Toronto, Canada.
    Aruffo E; Yuan P; Tan Y; Gatov E; Moyles I; Bélair J; Watmough J; Collier S; Arino J; Zhu H
    BMC Public Health; 2022 Jul; 22(1):1349. PubMed ID: 35841012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact.
    Swan DA; Bracis C; Janes H; Moore M; Matrajt L; Reeves DB; Burns E; Donnell D; Cohen MS; Schiffer JT; Dimitrov D
    Sci Rep; 2021 Jul; 11(1):15531. PubMed ID: 34330945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations.
    Kumar CK; Balasubramanian R; Ongarello S; Carmona S; Laxminarayan R
    PLoS One; 2022; 17(7):e0271103. PubMed ID: 35830457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A generalized distributed delay model of COVID-19: An endemic model with immunity waning.
    Iyaniwura SA; Musa R; Kong JD
    Math Biosci Eng; 2023 Jan; 20(3):5379-5412. PubMed ID: 36896550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
    Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
    BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana.
    Ofori SK; Schwind JS; Sullivan KL; Chowell G; Cowling BJ; Fung IC
    Pathog Glob Health; 2024 May; 118(3):262-276. PubMed ID: 38318877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.
    Cai J; Yang J; Deng X; Peng C; Chen X; Wu Q; Liu H; Zhang J; Zheng W; Zou J; Zhao Z; Ajelli M; Yu H
    Emerg Microbes Infect; 2022 Dec; 11(1):1205-1214. PubMed ID: 35380100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A COVID-19 vaccination model for Aotearoa New Zealand.
    Steyn N; Plank MJ; Binny RN; Hendy SC; Lustig A; Ridings K
    Sci Rep; 2022 Feb; 12(1):2720. PubMed ID: 35177804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.